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Metabolic risk factors and renal 
disease
JR Sowers1
Accumulating evidence supports that components of the metabolic 
syndrome coexist with both albuminuria and chronic kidney 
disease (CKD). The article by Tomaszewski et al. indicates that 
this interrelation exists in young obese men before overt renal or 
cardiovascular disease and also suggests that early treatment of 
hypertension is especially compelling to prevent the evolution of 
renal hyperfiltration to CKD.
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In addition to the generally recognized 
relationship between the metabolic 
syndrome and the future development 
of type 2 diabetes and cardiovascular 
disease, there is emerging evidence of 
an important relationship among the 
metabolic syndrome, obesity, and both 
albuminuria and chronic kidney disease 
(CKD).1–10 Early data suggesting this 
relationship1,2 have been confi rmed in 
large population-based studies.3–8 For 
example, the relationship between body 
mass index and end-stage renal disease 
(ESRD) was observed in a Japanese pop-
ulation of over 100,000 people followed 
for 17 years. Th e cumulative incidence 
of ESRD increased signifi cantly with ris-
ing body mass index; aft er adjustment 
for age, systolic blood pressure, and 
proteinuria, the odds ratio of body mass 
index for developing ESRD was 1.273 in 
men.3 Likewise, in 10,096 nondiabetic 
participants in the Atherosclerosis Risk 
In Communities Study, the odds ratio 
for developing CKD in those with the 
metabolic syndrome compared with 
those without the syndrome was 1.43.6 
Similarly, in a cohort of 320,252 adults 
from the United States followed up over 
a 15- to 35-year period, the rate of ESRD 
increased in a manner proportional to 
rising body mass index.7 These data 
confi rm the original observation that 
metabolic syndrome risk factors (ele-
vated triglycerides and low levels of 
high-density lipoprotein cholesterol) 
accelerate progression to ESRD.1
Increasing components of the meta-
bolic syndrome augment the risk for 
microalbuminuria4 and proteinuria.5 
For example, the association between 
components of the metabolic syndrome 
and the risk for microalbuminuria, as 
well as CKD, was assessed in persons 
participating in the Third National 
Health and Nutrition Examination 
Survey (NHANES III).4 In multivari-
ate-adjusted analysis, the odds ratio for 
microalbuminuria and CKD was 1:89 
and 2:60, respectively. Further, the risk 
for microalbuminuria and CKD was 
proportional to the number of individ-
ual components of the metabolic syn-
drome. Similar observations were made 
in a Japanese population in which the 
infl uence of the metabolic syndrome 
was documented in men younger than 
60 years.8
Tomaszewski and colleagues11 (this 
issue) have now advanced our under-
standing of these relationships between 
metabolic and renal disease risk factors. 
Th ey carefully phenotyped 1,572 young 
(mean age 18.4 years), relatively healthy 
men for metabolic risk factors and renal 
function as analyzed by calculated cre-
atinine clearance based on the Cock-
croft –Gault equation. Th ey observed 
that enhanced metabolic risk — clus-
tering of at least three metabolic risk 
factors — was present in 8.7% of these 
young men and was associated with an 
odds ratio of 6.9 for glomerular hyperfi l-
tration. Th is early renal abnormality was 
associated with adiposity (leptin levels 
and anthropometric determinants) and 
elevated blood pressure, each compo-
nents of the metabolic syndrome.
In their discussion of the observed 
associations,11 the authors propose 
that a major driver of hyperfi ltration 
is probably adipose tissue — a source 
of infl ammatory adipokines and leptin, 
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which stimulate glomerular hyperten-
sion and remodeling (Figure 1).9,10 
Indeed, obesity — in particular, vis-
ceral-type adiposity — is characterized 
by dysfunctional adipose tissue and is 
a known source of infl ammatory adi-
pokines, including components of the 
renin–angiotensin system, tumor necro-
sis factor-α, interleukin-1, interleukin-
6, leptin, and resistin, all of which have 
been implicated in insulin resistance.9 
Th e resulting decreased insulin sensi-
tivity and hyperinsulinemia, in con-
junction with hypertension, contribute 
to glomerular mesangial expansion, 
podocyte remodeling, loss of slit pore 
diaphragm integrity, and basement 
membrane thickening, all of which can 
lead to glomerulosclerosis and tubu-
lointerstitial injury (Figure 1).9,10
Activation of the renin angiotensin 
aldosterone system (RAAS) also con-
tributes to this early glomerular and 
tubulointerstitial remodeling/injury, 
in part through generation of reactive 
oxygen species.10 Whaley-Connell et 
al.10 recently reported that angiotensin 
II increases NADPH oxidase/reactive 
oxygen species and that this is a major 
contributor to podocyte eff acement and 
loss of slit pore diaphragm integrity, 
leading to albuminuria. Angiotensin 
II and aldosterone, as well as infl am-
matory adipokines, contribute to renal 
fi brosis as well as glomerular and tubu-
lointerstitial remodeling and injury.9 
Other potential actions of an activated 
renal RAAS include increased tubular 
sodium reabsorption, renal vasocon-
striction,   altered tubuloglomerular 
feedback as well as pressure induced 
changes in sodium excretion (Figure 1). 
Th ese renal alterations, in turn, can pro-
mote systemic vascular infl ammation 
and endothelial dysfunction, as well as 
worsening hypertension, resulting in a 
progressive cardiovascular–renal injury 
feedback loop.9
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Figure 1 | Relationship between obesity and insulin resistance/compensatory 
hyperinsulinemia, components of the metabolic syndrome, and the development of 
renal injury, chronic kidney disease, end-stage renal disease, and cardiovascular disease. 
Insulin resistance and compensatory hyperinsulinemia are at the root of activation of the 
renin–angiotensin system (RAS), oxidative stress, low-chronic systemic inflammation, glomerular 
hypertension, microalbuminuria, matrix expansion, and fibrosis. AT1R, angiotensin II type 1 
receptor; CRP, C-reactive protein; ESRD, end-stage renal disease; ET-1, endothelin-1; IL, interleukin; 
NADPH, ; NO, nitric oxide; PAI-1, plasminogen activator inhibitor 1; RAAS, ; ROS, reactive oxygen 
species; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; tPA, tissue-type 
plasminogen activator.
Obesity and insulin resistance also 
lead to an imbalance in the endogenous 
fi brinolytic system, with elevation of the 
levels and activity of plasminogen acti-
vator inhibitor 1 and relative reductions 
in plasminogen activator activity.9 In 
animal models, increased plasminogen 
activator inhibitor 1 has been demon-
strated to inhibit matrix metalloprotei-
nases, leading to impaired glomerular 
extracellular matrix degradation, with 
subsequent mesangial matrix expan-
sion and fibrosis.9 Indeed, elevated 
plasma levels of both plasminogen 
activator inhibitor 1 and other coagu-
lation factors, such as factor VII, have 
been associated with increased urinary 
protein excretion. Th us, obesity, insu-
lin resistance, and hypertension pro-
mote the progression of renal disease; 
and Tomaszewski et al.11 emphasize the 
fact that this association occurs early in 
young persons.
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